Javed Butler

Potential Patient Eligibility for Hospital at Home for Management of Worsening Heart Failure in the United States

Hubert B. Haywood, Iyanuoluwa Ayodele, Gregg C. Fonarow, Brooke Alhanti et autres

us, ca (code pays fourni par la source)

Correction to: Hypertensive acute heart failure: a critical perspective on definition, epidemiology, pathophysiology, and prognosis—a narrative review: a joint session with the Romanian Society of Cardiology (part II)

Oliviana Geavlete, Sean P. Collins, Alexandre Mebazaa, Linda Ye et autres

International audience

ro, us, fr, it, pl, rs, il, es, Égypte, si, se, tr (code pays fourni par la source)

Abstract 4369800: Association of Inflammatory Hypertension with Left Ventricular Hypertrophy in Black Adults from the Genetic Epidemiology Network of Arteriopathy Study

Laibah Khan, Seth T. Lirette, Syed Sarmad Javaid, B. Gwen Windham et autres

Background: Hypertension and systemic inflammation are independently associated with adverse cardiovascular outcomes. While hypertension is a known risk factor for left ventricular (LV) hypertrophy, the role of inflammation in LV structural changes remains unclear. It is also uncertain whether concomitant inflammation and …

us (code pays fourni par la source)

Abstract 4367950: Intensive lifestyle intervention, MASLD, and cardiovascular outcomes in type 2 diabetes and overweight or obesity: the Look Action for Health in Diabetes (Look AHEAD) trial Liver Ancillary Study

Zainali S. Chunawala, Kershaw V. Patel, Jeanne M. Clark, Lisa B. VanWagner et autres

Introduction: Lifestyle modification with weight loss is recommended in type 2 diabetes (T2D) with metabolic dysfunction-associated steatotic liver disease (MASLD). However, the effects of an intensive lifestyle intervention (ILI) targeting weight loss on MASLD in T2D has not been fully characterized. Furthermore, …

us, fr (code pays fourni par la source)

Abstract 4359292: Aldosterone dysregulation is associated with uncontrolled hypertension: Insights from the real-world BREAKTHROUGH Hypertension Study

Francesco Fioretti, Kendall A. P. Hammonds, Monica Bennett, Jason A Ettlinger et autres

Background: Association between serum aldosterone levels and uncontrolled hypertension in a real-world diverse population remains understudied. Aim: To evaluate the relationship between systolic blood pressure (SBP) and aldosterone dysregulation among patients with essential hypertension. Methods: Patients with essential hypertension who underwent serum …

us (code pays fourni par la source)

Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction

João Pedro Ferreira, Stefan D. Anker, Javed Butler, Francisco Vasques‐Nóvoa et autres

fr, de, us, pt, gb, gr (code pays fourni par la source)

Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper

Jagat Narula, Javed Butler, Mogamat‐Yazied Chothia, D. Banerjee et autres

The clinical impact of diabetes medications, including sodium-glucose cotransporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide 1 receptor agonists on cardiovascular and kidney disease outcomes has focused attention on the interrelatedness of kidney and heart health, both within and outside the …

us, Afrique du Sud, gb, Tunisie, fr, Nigéria, ch, be (code pays fourni par la source)

Semaglutide and Exercise Function in Obesity-Related HFpEF

Barry A. Borlaug, Dalane W. Kitzman, Shachi Patel, Khaja Chinnakondepalli et autres

BACKGROUND: Exercise function quantified by 6-minute walk distance (6MWD) is severely impaired in patients with heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: This prespecified secondary analysis of pooled data from the STEP-HFpEF Program (Research Study to Investigate How Well Semaglutide Works …

us, gb, ca, es, dk (code pays fourni par la source)

Optimization of Renin-Angiotensin System Inhibitors and Mineralocorticoid Receptor Antagonists in Patients with CKD and Heart Failure at High Risk for Hyperkalemia: Data from the CARE-HK in HF Registry

Ghazal Z. Quinn, Stephen John Greene, Andrew J. Sauer, Stefan D. Anker et autres

Background: Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular (CV) disease which accounts for a large number of deaths in this population. Key prevention therapies include renin–angiotensin system inhibitors (RASis) and mineralocorticoid receptor antagonists (MRAs), but their …

us, de, gb, au, pt, br, it, ch (code pays fourni par la source)

Acute Heart Failure Care – a Consensus Series of an International Experts' Group

Gad Cotter, Jan Biegus, Marat Fudim, Òscar Miró et autres

The care of patients hospitalized for acute heart failure (AHF) has been largely unchanged from the early 1960s until a few years ago, consisting mainly of oxygen and diuretics supplemented sometimes by other vasoactive drugs. These treatments, although effective in the short …

fr, us, pl, es, ca, it, ro, br, Cameroun, in, id, jp, se, Afrique du Sud, cn (code pays fourni par la source)

Early in-Hospital Treatment of Acute Heart Failure. Part 2 of the International Expert Opinion Series on AHF Management

Anika S. Naidu, Andrew P. Ambrosy, Gad Cotter, Edimar Alcides Bocchi et autres

Acute heart failure (AHF) remains a major global health challenge, contributing significantly to morbidity, mortality and healthcare resource utilization. It is one of the leading causes of hospitalization, with persistently high readmission rates underscoring the need for improved early management strategies. Despite …

us, fr, br, ro, Cameroun, in, es, id, ca, it, jp, se, Afrique du Sud, cn, pl (code pays fourni par la source)

Heart Failure Outcomes and Empagliflozin Effects in Patients with Heart Failure and Reduced Ejection Fraction in Sinus Rhythm or Atrial Fibrillation: Data from EMPEROR-Reduced

Michael R. R. Böhm, Javed Butler, Amr Abdin, João Pedro Ferreira et autres

AIMS: Empagliflozin reduces cardiovascular death (CVD) or hospitalization for heart failure (HHF), slows estimated glomerular filtration rate (eGFR) decline and improves quality of life (QoL) in heart failure with reduced ejection fraction (HFrEF). Whether the effect of empagliflozin is consistent according to …

de, us, gr, fr, pt, gb, Égypte, cn, no (code pays fourni par la source)